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Folate Deficiency Leading to Severe Neurologic Disease
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Ulrich Pannicke,7 Karl-Peter Hopfner,8 Eva-Maria Rump,9 Zuleya Ayric,10 Elisabeth Kohne,1
Klaus-Michael Debatin,1 Yvo Smulders,11 and Klaus Schwarz7,9
The importance of intracellular folate metabolism is illustrated by the severity of symptoms and complications caused by inborn disor-
ders of folatemetabolism or by folate deficiency.We examined three children of healthy, distantly related parents presenting withmega-
loblastic anemia and cerebral folate deficiency causing neurologic disease with atypical childhood absence epilepsy. Genome-wide
homozygosity mapping revealed a candidate region on chromosome 5 including the dihydrofolate reductase (DHFR) locus. DHFR
sequencing revealed a homozygousDHFRmutation, c.458A>T (p.Asp153Val), in all siblings. The patients’ folate profile in red blood cells
(RBC), plasma, and cerebrospinal fluid (CSF), analyzed by liquid chromatography tandem mass spectrometry, was compatible with
DHFR deficiency. DHFR activity and fluorescein-labeled methotrexate (FMTX) binding were severely reduced in EBV-immortalized lym-
phoblastoid cells of all patients. Heterozygous cells displayed intermediate DHFR activity and FMTX binding. RT-PCR of DHFR mRNA
revealed no differences between wild-type and DHFR mutation-carrying cells, whereas protein expression was reduced in cells with
the DHFR mutation. Treatment with folinic acid resulted in the resolution of hematological abnormalities, normalization of CSF folate
levels, and improvement of neurological symptoms. In conclusion, the homozygous DHFR mutation p.Asp153Val causes DHFR defi-
ciency and leads to a complex hematological and neurological disease that can be successfully treated with folinic acid. DHFR is neces-
sary for maintaining sufficient CSF and RBC folate levels, even in the presence of adequate nutritional folate supply and normal plasma
folate.Various inherited and acquired disorders affecting folate
uptake, transport, and metabolism have been described.
Nutritional folate deficiency is one of the most common
micronutrient deficiencies worldwide. Depending on the
severity of folate deficiency, it is associated with megalo-
blastic anemia, neurologic and mental disorders, cardio-
vascular disease, embryonic defects (in particular neural
tube defects), and, possibly, malignancies.1 Furthermore,
the importance of intracellular folate metabolism for
normal psychomotor and cognitive development is illus-
trated by the severity of symptoms in disorders of folate
metabolism, such as methylenetetrahydrofolate reductase
deficiency (MTHFR [MIM 236250]) or glutamate formimi-
notransferase deficiency (FTCD [MIM 229100]).2
Dihydrofolate reductase (DHFR [MIM 126060]) catalyzes
the reduction of dihydrofolate (DHF) to tetrahydrofolate
(THF) and, at a lower rate, of folic acid (FA) to DHF.
DHFR plays a key role in maintaining intracellular folate
homeostasis and is an important target for cytostatic drugs.
To date, three cases with initially suspected inherited
DHFR deficiency have been reported.3,4 Later analyses
revealed normal DHFR activity in one patient and the pres-
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patients.5,6 Follow-up for the third patient was not
reported. A distinct genetic defect associated with DHFR
deficiency has not been described.
We examined three children of healthy, distantly related
parents of European descent (Figure 1A). Patient 1 (VII-1 in
Figure 1) presented at age 11 without any clinical symp-
toms or findings. Peripheral-blood analysis revealed
macrocytosis without anemia (Table 1). Electroencephalo-
gram (EEG) at that time showed relatively slow 8–9/s
waves, particularly in the parieto-occipital region, and
intermittently repetitive generalized high-amplitude delta
waves but no epilepsy-specific potentials.
Patient 2 (VII-2 in Figure 1) presented at age 5 with
hemoglobin level at 56 g/l, mean corpuscular volume
(MCV) at 117 fl, 3.3% reticulocytes, and serum lactate
dehydrogenase activity at 2066 U/l without any congenital
physical abnormality. Bone marrow examination revealed
typical features of megaloblastic anemia. Serum folate,
cobalamin, transcobalamin I and II binding capacity, and
homocysteine, as well as urinary excretion of methylma-
lonic, orotic, and formiminoglutamic acid, were normal.
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Figure 1. Identification of the DHFR
c.458A>T Mutation in a Family and
Tertiary Structure of Human DHFR
(A) Pedigree of the family. Genetic analysis
was performed in the affected siblings and
their parents.
(B) Sequence analysis of DHFR exon 5
detected a homozygous base change,
c.458A>T, in all siblings and a heterozy-
gous mutation in both parents. Amplifica-
tions were performed with the HotStar-Taq
DNA Polymerase Kit (QIAGEN) with 35
cycles in a GeneAmp PCR System 9700
(Applied Biosystems). Sequencing reac-
tions were performed with BigDye Termi-
nator Cycle Sequencing Ready Reaction
(Applied Biosystems) and analyzed on an
ABI 3100 DNA Genetic Analyzer (Applied
Biosystems).
(C) Crystal structure of human DHFR
(yellow ribbon model with highlighted
secondary structure, Protein Data Bank
entry 2W3M) bound to NADPH (color-
coded stick model with green carbons,
white phosphors, red oxygens, and blue
nitrogens) and DHF (ruby stick model).
Themutation siteAsp153Val is highlighted
as amagenta stickmodel. Asp153 stabilizes
one side of the ‘‘F-G’’ loop, indicating that
the mutation alters DHFR activity by influ-
encing the fold and dynamics of the cata-
lytically important ‘‘F-G’’ and ‘‘Met20’’
loops. The figure was prepared with the
program PyMOL (Schro¨dinger).normalized hemoglobin levels and MCV. At age 8,
increasing learning difficulties developed and the patient
presented with short episodes of involuntary blinking
and winking, partially associated with impaired conscious-
ness. EEG revealed atypical childhood absence epilepsy
with eyelid myoclonia. A bone marrow smear still dis-
played mild megaloblastic changes despite an almost
normal peripheral-blood analysis (Table 1).
Patient 3 (VII-3 in Figure 1) had a complicated febrile
seizure at age 2. Blood analysis was normal apart from
marked macrocytosis with MCV 109 fl. Physical examina-The American Journal of Human Gention did not reveal any pathological
findings. Subsequent psychomotor
and cognitive development was
normal. At age 5, the girl presented
with frequent episodes of impaired
vision, blinking, and squinting asso-
ciated with impaired consciousness
and repetitive eyeball movements
during sleep. EEG showed severe
pathologic changes compatible with
an atypical childhood absence
epilepsy with eyelid myoclonia.
Blood examination still showed iso-
lated macrocytosis, whereas a bone
marrow smear displayed megalo-
blastic changes (Table 1). The girlwas treated with FA (5 mg per day) after consideration of
the apparent effectiveness of FA in her brother, who was
neurologically asymptomatic at that period.
After the occurrence of neurologic symptoms in patient
2 despite FA supplementation, 5-methyltetrahydrofolate
(5-MTHF) and neurotransmitter concentrations in the
cerebrospinal fluid (CSF) were determined for further
assessment of the metabolic changes of the disease.
5-MTHF analysis was performed precisely as previously
described.7 It revealed very low 5-MTHF in patient 1. In
patients 2 and 3, CSF 5-MTHF was undetectable despiteetics 88, 226–231, February 11, 2011 227
Table 1. Hematological Parameters, Total RBC Folate, and RBC Folate Metabolites and CSF 5-MTHF before and after 5-FTHF Substitution
RBC Folates CSF










Mother 149 89 773 760 12.7 0
Father 165 92 342 328 13.6 0
DHFR p.D153V homo.: untreated
Pt. 1 135 108 66 55 11.3 0 13.6
DHFR p.D153V homo.: treated with FA
Pt. 2 132 92 204a <5
Pt. 3 144 99 152a <5
DHFR p.D153V homo.: treated with 5-FTHF
Pt. 1 139 90 241 165 31.0 46 n.e.
Pt. 2 153 80 641 153 398 92 61
Pt. 3 135 89 702 374 226 102 59
Reference range 111–166 76–90 264–1153b 264–1086 0–67 0 41–117
5-FTHF, 5-formyltetrahydrofolate. NonmethylTHF (nonmethyltetrahydrofolate) contains 5,10-methenylTHF þ 5-formylTHF þ 10-formylTHF þ 5,10-methyle-
neTHF þ THF. n.e., not examined.
a Analyzed by chemiluminescence immunoassay (CLIA, Roche Diagnostics; assay-dependent normal values: 397–1589).
b Assay-dependent normal values for LC-MS/MS.preceding FA treatment (Table 1). Total red blood cell (RBC)
folate was low in all patients. Initially, treatment with
folinic acid (5-formyltetrahydrofolate; 5-FTHF) at 1 mg/kg
per day resulted in CSF 5-MTHF normalization in patients
2 and 3; patient 1 was not reexamined. Total RBC folate
increased in all patients (Table 1), associated with normal-
ization of MCV and bone marrow morphology. Subse-
quently, patient 1 received 5-FTHF very irregularly. Three
years later, he presented with focal epilepsy as his first clin-
ical impairment. In patient 2, 5-FTHF treatment led to
improved school performance, but persistent epilepsy.
Patient 3 became transiently independent of anticonvul-
sive treatment and had no additional neurological symp-
toms. Later, irregular 5-FTHF treatment was associated
with the recurrence of epileptic symptoms. The clinical
and biochemical features of the patients were suggestive
for an inherited disorder of folate transport or metabolism.
By genomic sequencing, we excluded FOLR1 mutations
known to cause congenital cerebral folate deficiency
(CFD [MIM 613068]).8
Consistent with a recessive inheritance model, we per-
formed homozygosity mapping by using genome-wide
SNP analysis performed on the Affymetrix GeneChip
platform. This and all subsequent examinations were
performed in accordance with the ethical standards of
the ethics committee of the University of Ulm. Written
informed consent was obtained from both parents.
Genome-wide SNP analysis revealed a short overlap on
the long arm of chromosome 2 and a second common
region on the long arm of chromosome 5 (nucleotide228 The American Journal of Human Genetics 88, 226–231, February79613515–nucleotide 82033415, Human Genome
Assembly, NCBI Human Genome Browser, build 36
[hg18]). This region, spanning 2.42 Mb, contains 28
known genes, including DHFR, the gene encoding for
dihydrofolate reductase. Another gene locus known to be
associated with folate transport or metabolism was not
found within the overlapping homozygous regions.
Genomic sequencing of DHFR exons and neighboring in-
tronic nucleotides was performed after genomic DNA
PCR reactions (for primer sequences, see Table S1 available
online). Sequence analysis revealed a homozygous DHFR
mutation, c.458A>T, in exon 5 (RefSeq NM_000791.3)
leading to a p.Asp153Val substitution in all siblings, thus
affecting an amino acid that, according to the Homolo-
Gene database, is highly conserved (Figure 1B). The muta-
tion has been deposited to the NCBI dbSNP. Both parents
(VI-2 and VI-3 in Figure 1) are heterozygous for the muta-
tion. The mutation was not detected in 120 control
samples.
DHFR possesses an a/b fold with a central 8-stranded
sheet, flanked by four a helices (Figure 1C). DHF and
NADPH cofactor are bound in a deep cleft (active site cleft)
that partitions the structure into two subdomains. Two
prominent loops, denoted ‘‘Met20’’ and ‘‘F-G loop,’’
emerge from one subdomain and form a lid that buries
and positions NADPH’s nicotinamid moiety in the cleft
for hydride transfer. A variety of studies indicate that the
dynamics of conformational states of these active site
loops are critical for efficient catalysis.9 Asp153 is situated
at the C-terminal end of the ‘‘F-G’’ loop, which connects11, 2011
b sheets F and G. It forms a hydrogen bond with the back-
bone nitrogen of Gly155, thereby stabilizing a helical turn
that is involved in anchoring sheet G and loops ‘‘F-G’’ as
well as ‘‘G-H’’ to the remainder of the structure. Val153
will lack this hydrogen bond as well as the negative charge.
The mutation likely affects fold, conformational stability,
and dynamics of the ‘‘F-G’’ loop and its closely associated
Met20 loop, resulting in an enzyme with reduced catalytic
efficiency.
Assuming DHFR deficiency, we analyzed folate metabo-
lites in RBCs and plasma by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) as previously
described.10 This assay distinguishes 5-MTHF, FA (sum of
FA and DHF, which converts to FA during assay), nonme-
thylTHF, and unsubstituted THF. Total RBC folate was
obtained by addition of the separate folate fractions or
by a chemiluminescence immunoassay. Before treatment,
patient 1 had low RBC folates despite normal plasma
folates (Table 1). During 5-FTHF treatment, RBC 5-MTHF
remained low in all patients. In addition, nonmethylTHF
and FA were present. Appreciable concentrations of non-
methyl folates in RBCs are normally observed only in indi-
viduals with the methylenetetrahydrofolate reductase
(MTHFR [MIM 607093]) 677 TT but not the MTHFR 677
CC genotype.11 The latter genotype was found in all
siblings. Therefore, the occurrence of non-methylTHF,
which includes 5-FTHF, is probably caused by 5-FTHF treat-
ment and not by DHFR deficiency. During 5-FTHF
treatment, FAþDHF was remarkably high in RBCs,
whereas THF remained low, which supports impaired
DHF-to-THF conversion. DHF is the likely source for the
measured FAþDHF, because no FA was used at the time
and spontaneous formation of FA in vivo is believed to
be virtually absent. Given that THF is the sole substrate
for polyglutamate synthase and that polyglutamation is
required for cellular storage of folates, the insufficient
supply of THF from DHF may explain low total RBC folate
levels.
Plasma and CSF homocysteine (Hcy) and methionine
were normal. Apparently, in this situation, with normal
nutritive folate supply and normal plasma folate, Hcy
regulation by S-adenosylmethionine viaMTHFR and cysta-
thionine beta-synthase (CBS [MIM 618833] pathways is
sufficient to compensate for dysfunctional DHFR. This is
in contrast to the Hcy increase observed in patients treated
withmethotrexate (MTX), which represents a high-affinity
substrate for DHFR. However, because MTX is inhibiting
not only DHFR but also other folate-related transport
proteins and enzymes (including MTHFR, dihydropteri-
dine reductase, etc.), its effect on Hcy is certainly of
a more complex nature than being due to only DHFR inhi-
bition. Neopterin, biopterin, and neurotransmitter levels
in the CSF and S-adenosyl-methionine and S-adenosyl-
homocysteine concentrations in the plasma and in RBC
were all within the normal range. Leukocyte global DNA
methylation, determined by LC-MS/MS12 and expressed
as the methyl-cytosine percentage of total cytosine, wasThe Americaalso normal and not influenced by 5-FTHF substitution
(data not shown).
To examine DHFR function directly, we studied the
formation of THF from DHF in EBV-immortalized lympho-
blastoid cells and fibroblasts from patients and controls.
Cells were incubated with NADPH and DHF, then
stabilized with mercaptoethanol and frozen. Cells were
lysated by freeze-thaw cycles. After centrifugation, the
supernatant was acidified, an internal standard ([13C5]-5-
methenylTHF) was added, and proteins were removed.
THF concentration was determined by LC-MS/MS.10
DHFR activity in lymphoblastoid cells was severely
reduced to less than 10% of control levels in all patient
cells, whereas cells of the heterozygous mother (VI-3 in
Figure 1) exhibited DHFR activity close to the lower limit
of the control range (Figure 2A). A confirmation of these
results in fibroblasts was not possible because under the
assay conditions that were used, DHFR activity in fibro-
blasts was very low, even in wild-type cells (data not
shown). Nevertheless, in the context of the genetic and
biochemical data, the results for DHFR activity obtained
in lymphoblastoid cells have to be regarded as representa-
tive for the disorder.
To assess binding of the substrate to the mutated DHFR,
we performed a fluorescence-based assay,13 showing that
binding of fluorescein-labeled methotrexate (FMTX) to
DHFR is severely reduced in lymphoblastoid cells of all
three patients and slightly decreased in cells of the hetero-
zygous mother (Figure 2B).
To assess whether the reduced DHFR activity was caused
by an altered mRNA and protein expression, we performed
RT-PCR and immunoblot analyses (Figures 2C and 2D). In
contrast to the DHFR mRNA expression, which did not
differ between patients and controls (Figure 2C), protein
expression was reduced in mutated cells as compared to
wild-type cells. Immunoblotting revealed reduced intact
DHFR in heterozygous (~70%) as well as in homozygous
(~20%–50%) lymphoblastoid cells (Figure 2D). Protein
reduction was less severe in mutated fibroblasts (heterozy-
gous ~90%, homozygous 70%–80%). Probably, the muta-
tion is responsible for the reduced protein expression by
changing protein folding, binding to chaperones, or influ-
encing the stability of other protein complexes involving
DHFR.
However, both the DHFR activity and FMTX binding
show an equally severe DHFR dysfunction, whereas the
variable reduction of protein expression is only moderate
(lymphoblasts) or mild (fibroblasts). Therefore, the interin-
dividual protein variation probably reflects differences that
are not intrinsic to DHFR but also depend on extrinsic
factors that target DHFR directly or target its binding to
stabilizing intracellular factors and, hence, contribute to
the endogenous variability of cellular protein processing.
With regard to the equally severe reduction of DHFR
activity, the variation of the moderate protein reduction
as a single factor cannot explain the phenotypic variability
seen in patients with DHFR deficiency.n Journal of Human Genetics 88, 226–231, February 11, 2011 229
Figure 2. Functional Characteristics of
the DHFR Mutant
(A) DHFR activity in lymphoblastoid cells
of control individuals (DHFR wild-type),
the patients’ mother (heterozygous for
DHFR p.Asp153Val ¼ p.D153V), and the
three siblings (homozygous for DHFR
p.D153V) as measured by the formation
of THF out of DHF per hour and mg
protein. A DHFR Kit (Sigma) was used for
the assay (for details, see text).
(B) Fluorescence-activated cell sorting
(FACS) analysis of lymphoblastoid cells
after incubation with 10 mM fluorescein-
labeled methotrexate (FMTX; Invitrogen).
Cells were additionally stained with 7-
Aminoactinomycin D (7-AAD; 2,5 mg/ml)
to sort vital cells for FMTX-FACS analysis.
(C) DHFR RT-PCR after isolation of mRNA
from lymphoblastoid cells of the heterozy-
gous mother (lanes 2 and 9), the three
homozygous siblings (lanes 3–5 and
10–12; patients 1–3), and a control indi-
vidual (DHFR wild-type) (lanes 6 and 13)
revealed a single ~450 bp cDNA fragment
(agarose gel, 1.5%). cDNA was synthesized
with the use of random hexamers and
Superscript II RNase HT (Invitrogen) at
42C for 50 min. DHFR PCR was per-
formed in 35 cycles at 55C (for primer
sequences, see Table S1).
(D) DHFR protein expression in DHFR p.D153V heterozygous (lane 1, mother) and homozygous (lane 2, patient 2; lane 3, patient 3;
lane 4, patient 1) lymphoblastoid cells (upper panel) and fibroblasts as compared to control cells (stepwise dilution of total blotted
protein: lanes 5–9). In the lower panel, lane 4 is waste because fibroblasts from patient 1 were not available. After separation on
a 15% SDS gel, proteins were blotted on an Immobilon-P membrane (Millipore). Primary antibodies (DHFR [E-18], MAPK1 [D-2], Santa
Cruz Biotechnology) were diluted to a concentration of 1:200 and 1:10,000; secondary antibodies (anti-goat IgG-HRP, Santa Cruz
Biotechnology; goat anti-mouse IgG [HþL]-HRP, BioRad), 1:2000 and 1:10,000, respectively. Blots were developed with the use of the
Super Script West Pico Chemoluminescent Substrate Kit (Thermo Scientific).The causes underlying the different phenotype expres-
sion in individual patients remain obscure. Additional
DHFR alterations that could possibly modify the effect of
the DHFR p.Asp153Val mutation were excluded (data not
shown). MTHFR activity in homozygous and heterozygous
lymphoblastoid cells carrying the DHFR mutation, as
determined by LC-MS/MS, did not differ from that in
wild-type cells (data not shown).
Biopterin and folate metabolism appear to overlap at
several points, and previous in vitro studies demonstrated
that human dihydropteridine reductase (DHPR [MIM
612676]) may function in THF metabolism.14,15 We there-
fore analyzed DHPR activity in dried blood samples16 from
the three siblings and found that it did not differ from that
of controls (data not shown). However, DHPR activity in
the peripheral blood may not adequately reflect its activity
in the brain.17
To summarize, we have shown that the homozygous
DHFR mutation p.Asp153Val causes DHFR deficiency and
leads to a complex neurological and hematological disease
in the absence of any malformation, including neural tube
defects. Apparently, intact intracellular folate metabolite
recycling through DHFR is of central importance for main-
taining sufficient CSF and RBC folate levels, even in the
presence of adequate nutritional folate supply and normal230 The American Journal of Human Genetics 88, 226–231, Februaryplasma folate. CSF folate levels were comparable to those of
patients with congenital or acquired cerebral folate defi-
ciency who present in infancy or early childhood with
severe neurological symptoms.8,18 It seems possible that
in CFD patients, not only the low CSF folate but also other
changes associated with folate receptor dysfunction
contribute to the early disease manifestation and the
more severe phenotype.
In conclusion, we have described patients with inherited
DHFR deficiency due to homozygous DHFRmutation. This
condition merits consideration in young patients who
present with unexplained macrocytic anemia, moderately
severe developmental disorders, and epilepsy.
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